VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | Letermovir prophylaxis to prevent infection after HSCT

Michael Boeckh, MD, PhD, Fred Hutchinson Cancer Research Center, Washington, WA, provides an overview of current views surrounding the use of letermovir as secondary prophylaxis after hematopoietic stem cell transplantation (HSCT). Whilst the antiviral drug may be useful for patients with a high viral load or who have high-grade immunosuppression, there is no reliable data on its efficacy and additional research is required to elucidate its long-term effects. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter